Abstract
Thyroid cancer is the most common type of endocrine cancer. Chemokine-like factor (CKLF)-like MARVEL transmembrane domain containing 6 (CMTM6) is recognized as one of its potential immunotherapy targets. The purpose of this study was to investigate the role and molecular mechanism of CMTM6 in regulating the development of thyroid cancer cells. In this study, expression levels of CMTM6 and the sodium/iodide symporter (NIS) were detected by qRT-PCR. Additionally, colony formation assay and flow cytometry were used to detect cell proliferation and apoptosis, while expression levels of various proteins were assessed using Western blotting. Further, the apoptosis and invasion capacity of cells were investigated by scratch and transwell experiments. Finally, the effect of CMTM6 on the epithelial-mesenchymal transition (EMT) of thyroid cancer cells was determined by immunofluorescence assay, which measured the expression levels of epithelial and mesenchymal phenotypic markers. The results of qRT-PCR experiments showed that CMTM6 was highly expressed in thyroid cancer tissues and cells. In addition, knockdown of CMTM6 expression significantly increased NIS expression. Function experiments demonstrated that small interfering (si)-CMTM6 treatment inhibited the proliferation, migration, invasion, and EMT of thyroid cancer cells, while promoting apoptosis of FTC133 cells. Furthermore, mechanistic studies showed that mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) phosphorylation were inhibited by si-CMTM6, as demonstrated by Western blot experiments. In conclusion, our findings demonstrated the role of CMTM6 in the metastasis of thyroid cancer. Briefly, CMTM6 exerts its tumor-promoting effect through the MAPK signaling pathway and could potentially be used as a valuable biomarker for thyroid cancer diagnosis and prognosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The dataset used and/or analyzed in this study is available from the corresponding author on reasonable request.
References
Ancker OV, Wehland M, Bauer J, Infanger M, Grimm D (2017) The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors. Int J Mol Sci 18:625. https://doi.org/10.3390/ijms18030625
Chai W, Ye F, Zeng L, Li Y, Yang L (2019) HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells. J Exp Clin Cancer Res 38:325. https://doi.org/10.1186/s13046-019-1328-3
Cunha LL, Marcello MA, Rocha-Santos V, Ward LS (2017) Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocr Relat Cancer 24:T261–T281. https://doi.org/10.1530/ERC-17-0222
Hong CM, Ahn BC (2017) Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy. Front Endocrinol (lausanne) 8:260. https://doi.org/10.3389/fendo.2017.00260
Huang X, Xiang L, Wang B et al (2021) CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells. J Transl Med 19:120. https://doi.org/10.1186/s12967-021-02787-5
Jia L, Chen Y, Chen F et al (2022) Small activating RNA-activated NIS gene promotes (131)I uptake and inhibits thyroid cancer via AMPK/mTOR pathway. Pathol Res Pract 229:153735. https://doi.org/10.1016/j.prp.2021.153735
Jiao C, Li L, Zhang P et al (2020) REGgamma ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-beta pathway. Cell Death Differ 27:497–508. https://doi.org/10.1038/s41418-019-0367-9
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80. https://doi.org/10.1126/science.aaa6204
Kang J, Park JH, Kong JS, Kim MJ, Lee SS, Park S, Myung JK (2021) PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/beta-catenin signaling pathway. Am J Cancer Res 11:5485–5495 (https://www.ncbi.nlm.nih.gov/pubmed/34873474)
Lee H, Hodi FS, Giobbie-Hurder A et al (2017) Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res 5:1133–1140. https://doi.org/10.1158/2326-6066.CIR-17-0208
Li X, Chen L, Gu C, Sun Q, Li J (2020) CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ 8:e9536. https://doi.org/10.7717/peerj.9536
Li J, Hou H, Sun J, Ding Z et al (2023a) Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker. Funct Integr Genomics 23:105. https://doi.org/10.1007/s10142-023-01032-0
Li X, Zhou Y, Jiang Q et al (2023b) A novel scoring model based on RNA modification “writers” can predict the prognosis and guide immunotherapy in gastric cancer. Funct Integr Genomics 23:162. https://doi.org/10.1007/s10142-023-01098-w
Liang J, Li S, Li W et al (2022) CMTM6, a potential immunotherapy target. J Cancer Res Clin Oncol 148:47–56. https://doi.org/10.1007/s00432-021-03835-9
Liotti F, Kumar N, Prevete N et al (2021) PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. J Exp Clin Cancer Res 40:22. https://doi.org/10.1186/s13046-020-01818-1
Meng F, Su Y, Xu B (2020) Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer. Mol Oncol 14:2701–2712. https://doi.org/10.1002/1878-0261.12804
Muranushi R, Araki K, Yokobori T et al (2021) High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 112:3314–3323. https://doi.org/10.1111/cas.15004
Peng QH, Wang CH, Chen HM et al. (2021) CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer 9:e001638. https://doi.org/10.1136/jitc-2020-001638
Porter KJ, Gonipeta B, Parvataneni S et al (2010) Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins. J Cell Physiol 225:406–416. https://doi.org/10.1002/jcp.22289
Takeuchi H, Konnai S, Maekawa N et al (2020) Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers. Front Vet Sci 7:330. https://doi.org/10.3389/fvets.2020.00330
Wang S, Liang J, Lin Y, Yao R (2013) Differential expression of the Na(+)/I(-) symporter protein in thyroid cancer and adjacent normal and nodular goiter tissues. Oncol Lett 5:368–372. https://doi.org/10.3892/ol.2012.947
Wang X, Peng W, Li C, Qin R, Zhong Z, Sun C (2021) Identification of an immune-related signature indicating the dedifferentiation of thyroid cells. Cancer Cell Int 21:231. https://doi.org/10.1186/s12935-021-01939-3
Xiao M, Hasmim M, Lequeux A et al (2021) Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer. Cancers (Basel) 13:1165. https://doi.org/10.3390/cancers13051165
Xie F, Wang J, Zhang B (2023) RefFinder: a web-based tool for comprehensively analyzing and identifying reference genes. Funct Integr Genomics 23:125. https://doi.org/10.1007/s10142-023-01055-7
Yang L, Wang Y, Sun R et al (2020) ANGPTL4 Promotes the Proliferation of Papillary Thyroid Cancer via AKT Pathway. Onco Targets Ther 13:2299–2309. https://doi.org/10.2147/OTT.S237751
Yang F, Yu Y, Zhou H, Zhou Y (2023) Prognostic subtypes of thyroid cancer was constructed based on single cell and bulk-RNA sequencing data and verified its authenticity. Funct Integr Genomics 23:89. https://doi.org/10.1007/s10142-023-01027-x
Zhang GQ, Jiao Q, Shen CT, Song HJ, Zhang HZ, Qiu ZL, Luo QY (2021a) Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. Cancer Sci 112:997–1010. https://doi.org/10.1111/cas.14752
Zhang S, Yan Q, Wei S et al (2021b) CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 132:202–209. https://doi.org/10.1016/j.oooo.2021.02.019
Funding
This work was supported by the National Natural Science Foundation of China (No.81760427) and the Natural Science Foundation of Jiangxi Province (No. 20202BABL216037).
Author information
Authors and Affiliations
Contributions
NZ conceived and designed the study. XC performed the experiment and drafted the manuscript. HS, HL and LT performed the literature searching and data analysis. XC, HS and NZ discussed the results. XC and NZ revised the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent participate
Not applicable.
Animal ethics
Not applicable.
Conflicts of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, X., Shen, H., Liu, H. et al. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway. Funct Integr Genomics 24, 10 (2024). https://doi.org/10.1007/s10142-024-01298-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-024-01298-y